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Abstract
Background: Although the interferon-γ release assay (IGRA) has become a widely accepted means for the
diagnosis of latent tuberculosis infection (LTBI), the role of the IGRA in diagnosing active tuberculosis (ATB)
among human immunodeficiency virus (HIV)-seropositive individuals remains controversial. Previous analyses
did not set up rational inclusive criteria for screening articles with strict control groups and a gold standard
for ATB diagnosis. Therefore, we conducted a systematic review of the latest evidence to evaluate the accuracy of IGRA
for HIV-seropositive patients.
Methods: Initially, we searched the EMBASE, Cochrane and MEDLINE databases to find research articles published from
January 2000 to October 2015 that used the QuantiFERON-TB Gold In-Tube assay (QFT-IT) or the T-SPOT.TB assay
(T-SPOT) to diagnose ATB among HIV-seropositive individuals. We separately calculated the pooled sensitivity,
specificity, and proportion of indeterminate events and then summarized the results using forest plots to
estimate the accuracy of the QFT-IT and T-SPOT assays.
Results: A total of 1,743 studies were discovered after searching; 11 studies met our selection standards and
were included for meta-analysis. The pooled sensitivity and specificity of the QFT-IT assay were 69 % (95 % CI,
50–84 %, I2 = 85.22 %) and 76 % (95 % CI, 53–90 %, I2 = 98.16 %), respectively, and the optimum area under the
curve (AUC) was 0.78 (95 % CI, 0.74–0.82). The pooled sensitivity and specificity of the T-SPOT assay were 89 %
(95 % CI, 66–97 %, I2 = 94.48 %) and 87 % (95 % CI, 38–99 %, I2 = 97.92 %), respectively, and the AUC was 0.93
(95 % CI, 0.90–0.95). The pooled ratios of the indeterminate results of the QFT-IT and T-SPOT assays were 0.07
(95 % CI, 0.06–0.09, I2 = 74.8 %) and 0.19 (95 % CI, 0.15–0.24, I2 = 88.3 %), respectively, calculated using the fixed
effect model, and 0.08 (95 % CI, 0.06–0.12, I2 = 74.8 %) and 0.10 (95 % CI, 0.03–0.25, I2 = 88.3 %), respectively,
calculated using the random effects model.
Conclusions: The IGRA does not appear to be optimal for the clinical confirmation of ATB cases in HIV-seropositive
patients; however, the T-SPOT assay may have greater accuracy in distinguishing ATB cases among HIV-infected
individuals than the QFT-IT assay, while the QFT-IT assay appears to reduce the occurrence of indeterminate results.
Furthermore, modification and additional trial designs are required to improve diagnostic effectiveness.
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Background
Mycobacterium tuberculosis infection has become one of
the leading causes of mortality among patients living with
acquired immunodeficiency syndrome (AIDS) caused by
infection with the human immunodeficiency virus (HIV).
In fact, one third of deaths among HIV-seropositive pa-
tients are due to tuberculosis (TB). The World Health
Organization (WHO) reported 9.6 million TB cases world-
wide in 2014 and 1.2 million HIV-seropositive TB cases.
These cases were especially prominent in Africa, where
HIV-seropositive TB cases represented 74 % of the total
HIV/TB co-infections [1]. The high occurrence and mortal-
ity rates of TB among HIV-seropositive individuals urgently
require a novel approach to practical TB diagnostics [2].
The gold standard for active tuberculosis (ATB) diag-
nosis remains bacteriological positive culture of Myco-
bacterium tuberculosis in sputum, bronchoalveolar
lavage, and/or tissue biopsy; however, these methods are
time-consuming [3, 4]. It may also be difficult to obtain
an appropriate culture sample from HIV-seropositive in-
dividuals suffering from TB [5, 6]. Nevertheless, clinical
and radiographic manifestations of ATB lack reliability
among HIV-seropositive patients and tend to delay the
diagnosis of ATB and initiation of appropriate anti-TB
therapy [7, 8].
In the past 15 years, as an immunodiagnostic method,
the interferon-γ (IFN-γ) release assay (IGRA) was devel-
oped to distinguish patients suffering from TB. The
IGRA is a blood test that detects the immune response
to Mycobacterium tuberculosis-specific antigens (early
secreted antigenic target 6 kDa, or ESAT-6 and culture
filtrate protein 10 kDa or CFP-10) in vitro. Currently,
two commercial IGRAs are recommended and available
for diagnosing TB in the clinic: an enzyme-linked immu-
nospot assay [T-SPOT.TB assay (T-SPOT), Oxford
Immunotec, Abingdon, UK] and an enzyme-linked
immunosorbant assay [QuantiFERON-TB Gold In-Tube
assay (QFT-IT), Cellestis, Carnegie, Australia] [9]. How-
ever, the limitations of the IGRA for practical applica-
tions in clinical work have prompted widespread
controversy, particularly in immunocompromised popu-
lation. Thus, it is essential to perform a comprehensive
evaluation of the performance of the IGRA for diagnos-
ing ATB among HIV-seropositive individuals based on
latest evidence to guide clinicians.
We conducted a comprehensive systematic review and
meta-analysis of the latest evidence to evaluate the ac-
curacy of IGRA in diagnosing ATB among HIV-infected
patients to guide the application of the IGRA in im-
munocompromised population.
Methods
This systematic review and meta-analysis was conducted
within the guidelines of the preferred reporting items for
systematic reviews and meta-analyses (PRISMA) state-
ment [10]. Because this research was a systematic review
of published articles, ethical approval was not required.
Mycobacterium tuberculosis culture was adopted as the
gold standard for the diagnosis of ATB in this systematic
review.
Data sources and search strategy
We systematically searched all studies that estimated the
accuracy of the IGRA (using two commercial IGRAs:
QFT-IT and T-SPOT) for ATB among HIV-seropositive
adult individuals. We searched the EMBASE, Cochrane
and MEDLINE databases to find research articles pub-
lished from January 1, 2000 to October 30, 2015. Searches
were implemented using combinations of the following
terms: “tuberculosis”, “active tuberculosis”, “interferon-
gamma release assay”, “QFT-IT”, “T-SPOT”, “CFP-10”,
“ESAT-6”, “IGRA”, “acquired immunodeficiency syn-
drome”, “human immunodeficiency virus” and “HIV”. We
searched for additional references from review articles,
guidelines and conferences when necessary.
Fig. 1 Flowchart diagram of the search strategy for study selection.
IGRAs: Interferon-γ release assays; ATB: active tuberculosis
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Table 1 General characteristics of the reviewed studies and the primary results
Age (years)b CD4+ counts (cells/μL)c Assay resultse
Investigators Year Country ATB/non-ATB
patients enrolleda
ATB patients Non-ATB patients ATB patients Non-ATB patients IGRA methodd TP FP FN TN I
Aichelburg 2009 Austria 8/822 39 (32–47) 39 (32–47) 393 (264–566) 393 (264–566) QFT-IT 7 37 1 738 47
Davarpanah 2009 Iran 11/165 38 (23–60) 38 (23–60) 360 (34–1300) 360 (34–1300) QFT-IT 4 45 7 107 13
Veldsman 2009 South Africa 30/30 NR NR NR NR QFT-IT 9 11 15 16 9
Cattamanchi 2010 Uganda 112/100 33 (27–40) 33 (27–40) 49 (16–160) 49 (16–160) T-SPOT 61 34 23 40 54
Legesse 2010 Ethiopia 6/21 34.2 (18–70) 34.2 (18–70) NR NR QFT-IT 5 10 1 10 1
Leidl 2010 Uganda 19/109 33.4 ± 6 34.1 ± 8.3 182 (118) 283 (226) T-SPOT 17 59 0 46 6
QFT-IT 13 74 6 31 4
Tan 2010 Taiwan 9/30 39.6 (30–52) 39.1 (19–67) 112 (31–332) 145 (0–596) T-SPOT 8 2 1 28 0
Bua 2011 Italy 9/64 41 (21–63) 41 (21–63) 270 (4–897) 270 (4–897) QFT-IT 2 6 6 47 12
Rangaka 2011 South Africa 50/729 35 (31–40) 36 (31–42) 169 (98–239) 198 (136–315) QFT-IT 32 298 15 383 51
Lagrange 2013 India 38/54 38.0 (30.5-42.0) 38.0 (30.5-42.0) NR NR QFT-IT 26 19 3 29 15
Markova 2014 Bulgaria 13/52 43 (29 – 63) 37 (21–66) 195 (15–450) 248 (36–785) T-SPOT 8 0 1 48 8
QFT-IT 12 0 1 49 3
aAll patients in the study were HIV-seropositive. ATB, active tuberculosis
bThe values represent the means ± SD or medians with corresponding interquartile ranges (IQRs). NR, not reported in the study
cThe values represent the means ± SD or medians with corresponding IQRs
dIGRA, interferon gamma release assay. QFT-IT, QuantiFERON-TB Gold In-Tube assay. T-SPOT, T-SPOT.TB assay
















In this systematic review, two investigators (ZY. Huo
and L. Peng) independently completed a primary scan to
screen references that were potentially appropriate based
on the titles and abstracts. Studies that only evaluated
the performance of IGRA for diagnosing active TB in
HIV-seropositive patients on blood samples were in-
cluded. Then, a secondary selection was completed by
reviewing the full text of the article. Articles were ex-
cluded if one of the follow criteria was fulfilled: 1) the
study did not set up a non-ATB control group in HIV-
seropositive patients; 2) experiments were performed
with an older generation of the IGRA method, did not
use a commercial IGRA, or the cut-off values of the
IGRA were not the same; 3) ATB cases were not confirmed
by Mycobacterium tuberculosis culture; 4) the number of
HIV-seropositive individuals was less than 10; 5) studies
where screened individuals had received anti-TB therapy; 6)
repeat research by the same author; 7) original data was not
included; and 8) reports of prospective studies, conference
abstracts, reviews, guidelines, letter and case reports. All ci-
tations were screened and verified independently by two in-
vestigators. Group discussion took place when the two
investigators disagreed on the inclusive criteria of a citation.
Data extraction and quality assessment
Data from all included research studies were extracted
and crosschecked by two investigators independently.
The following data from English-language articles were
extracted: 1) author, publication year of article, calendar
period of research, and the nation where the research
was performed; 2) the age group of the enrolled partici-
pants; 3) the type of commercial IGRA studied; 4) the
proportion of ATB among HIV-seropositive participants
diagnosed by culture; and 5) the amount of indetermin-
ate, negative and positive results for each group among
the participants. The quality of all included studies was
evaluated using the quality assessment of diagnostic ac-
curacy studies-2 (QUADAS-2) checklist, which is a vali-
dated and widely used criterion for the diagnostic
accuracy of trials [11].
Statistical analysis
We adopted the standard methods recommended for
systematic meta-analyses of diagnostic test evaluations
[12, 13]. Statistical data analysis software programs
(Stata/MP 13.1 and R for windows 3.2.2) were used for
the meta-analysis. For each study, we separately calcu-
lated the sensitivity, specificity, and proportion of inde-
terminate events with the corresponding 95 %
confidence intervals (95 % CI). Then, we summarized
and synthesized these results using forest plots. Only
cases with a confirmed Mycobacterium tuberculosis diag-
nosis by direct culture were classified as ATB patients,
and the remaining cases were assumed to be non-ATB
patients. Indeterminate results were excluded prior to
calculating sensitivity and specificity if reported [14–16].
Statistically significant inconsistencies across articles
were estimated by adopting the I2 statistic to examine
the influence of authentic variability instead of errors as-
sociated with diagnostic sampling. The separated sensi-
tivity and specificity of a single test for each study were
used to generate a symmetric receiver operator charac-
teristic (SROC) curve, which summarized the overall test
performance and represented the variation occurring in
the diagnostic accuracy among studies [17–19].
Results
Search results and study characteristics
A total of 1,743 studies were identified after searching in
the EMBASE, Cochrane and MEDLINE databases. After
the full text of the articles was assessed for eligibility, 11
studies met our selection standards and were included
in the meta-analysis [20–30]. Figure 1 summarizes the
selection process for review articles with the detailed
number of articles in each step. All articles were original
publications and were published in English. The 11 se-
lected studies included a total of 2,481 HIV-seropositive
individuals with 305 culture-confirmed ATB cases.
Table 1 shows the characteristics of the reviewed studies
and the primary results. Nine studies estimated the per-
formance of the QFT-IT assay, whereas four studies esti-
mated the performance of the T-SPOT assay. Two
Fig. 2 Methodological quality evaluation results of 11 studies sorted
using the Quality Assessment of Diagnostic Accuracy Studies-2
(QUADAS-2) tool. See references [20–30] for details
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studies reported the performance of both the QFT-IT
and T-SPOT assays. Nine studies were performed in
high-burden counties (more than 40 cases per 100 thou-
sand population), whereas two studies were performed
in low/intermediate-burden countries (less than 40 cases
per 100 thousand population, specifically Austria and
Italy) [31]. Almost all studies reported a median CD4+
T-lymphocyte count of less than 400 cells/mm3, except
for three studies that did not report the median CD4+
counts in the text. Additional specific information with
respect to the studies included in this systematic review
is available upon request.
Quality of the selected studies
Figure 2 shows the quality of the studies included using
the QUADAS-2 tool. Of these 11 articles, 6 studies
showed a high risk of bias, whereas 4 studies showed a
high risk of applicability concerns. Additional informa-
tion about the quality of the overall studies is shown in
Fig. 2.
Fig. 4 Symmetric receiver operator characteristic (SROC) curve for
the QFT-IT assay. The SROC curve was derived by Stata/MP 13.1
Fig. 3 Forest plots of the pooled sensitivity and specificity of the QFT-IT assay for diagnosing ATB among HIV-seropositive individuals after
excluding indeterminate results. See references [20–28] for details
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Sensitivity and specificity of the QFT-IT
After precluding the indeterminate QFT-IT events, 9
studies with a total of 2,230 participants were incorpo-
rated to calculate the combined sensitivity and specificity
of the QFT-IT assays [20–28]. The pooled sensitivity of
the QFT-IT assay for active culture-confirmed TB in
HIV-seropositive individuals was 69 % (95 % CI: 50–
84 %, I2 = 85.22 %), and the pooled specificity was 76 %
(95 % CI: 53–90 %, I2 = 98.16 %, Fig. 3). We estimated
the pooled diagnostic performance of the QFT-IT assay
by generating SROC curves, which show the sensitivity
versus the specificity, and by calculating the correspond-
ing area under the SROC curves (AUC, Fig. 4). The
SROC curve for QFT-IT was not located near the desir-
able upper left corner, and the optimum AUC was 0.78
(95 % CI, 0.74–0.82).
Sensitivity and specificity of the T-SPOT
At the same time, the combined sensitivity of the T-
SPOT assay was calculated from four studies with a
total of 444 individuals after excluding the
Fig. 5 Forest plots of the pooled sensitivity and specificity of the T-SPOT assay for diagnosing ATB among HIV-seropositive individuals after
excluding indeterminate results. See references [27–30] for details
Fig. 6 Symmetric receiver operator characteristic (SROC) curve for
the T-SPOT assay. The SROC curve was derived by Stata/MP 13.1
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indeterminate events [27–30]. The pooled sensitivity
of the T-SPOT assay for active culture-confirmed TB
was 89 % (95 % CI, 66–97 %, I2 = 94.48 %), whereas
the pooled specificity of the T-SPOT assay was 87 %
(95 % CI, 38–99 %, I2 = 97.92 %, Fig. 5). We calculated
the SROC curve and the corresponding AUC for the
T-SPOT assay using Stata/MP 13.1 (Fig. 6). Although
the SROC curve for the T-SPOT assay was positioned
in the desirable upper left corner, and the AUC was
0.93 (95 % CI, 0.90–0.95), these results may not repre-
sent the authentic performance of the T-SPOT assay,
as evidenced by the high heterogeneity among the
studies (I2 = 94.48 and 97.92 %, for sensitivity and spe-
cificity, respectively) and the small number of inclu-
sive studies.
Indeterminate events
To estimate the occurrence of indeterminate events
using two commercial IGRAs, we calculated the pooled
ratio of indeterminate results using a data analysis soft-
ware program (R for Windows 3.2.2). The pooled ratio
of QFT-IT indeterminate events was 0.07 (95 % CI,
0.06–0.09, I2 = 74.8 %) when using the fixed effect
model; when using the random effects model, the
pooled ratio of the QFT-IT assay was 0.08 (95 % CI,
0.06–0.12, I2 = 74.8 %, Fig. 7). When using the fixed ef-
fect model, the pooled ratio of T-SPOT indeterminate
events was 0.19 (95 % CI, 0.15–0.24, I2 = 88.3 %); the
pooled ratio for the T-SPOT assay was 0.10 (95 % CI,
0.03–0.25, I2 = 88.3 %) when using the random effects
model (Fig. 8). Compared with the T-SPOT, the QFT-
IT assay appeared to reduce the percentage of indeter-
minate results among HIV-seropositive individuals.
Publication bias
The publication bias of the 11 included studies was eval-
uated and analyzed using Deeks’ funnel plot asymmetry
test (Figs. 9 and 10). Figure 9 indicates no significant
asymmetry for the QFT-IT assay (P = 0.47), which sug-
gested a low risk of publication bias for this assay. How-
ever, Fig. 10 shows an asymmetrical funnel plot for the
T-SPOT assay (P = 0.04), which indicates a potential risk
of publication bias.
Discussion
The results of our systematic review, which differ from
previous analyses, appear to suggest that the IGRA plays
a limited role in diagnosing ATB in HIV-seropositive
Fig. 7 Forest plot of the pooled ratio of QFT-IT indeterminate events using the fixed effects model and the random effects model. See references
[20–28] for details
Fig. 8 Forest plot of the pooled ratio of T-SPOT indeterminate events using the fixed effects model and the random effects model. See references
[27–30] for details
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patients. However, this meta-analysis is an update
and improves on previous articles in several respects
[14, 32]. Compared to previous studies, we included
the most recent publications prior to 2016 to perform a
comprehensive and objective evaluation of the IGRA and
set a more strict and rational inclusion criteria for this re-
view. The search strategy of our study was broader, and a
total of 1,743 studies were identified after comprehen-
sively searching three databases. After screening using our
precise inclusion criteria, only eleven studies met our
selection standards and were included in the meta-
analysis. Then, we used the latest validated quality assess-
ment checklist tool, QUADAS-2, to evaluate the risk of
bias and applicability concerns among the included stud-
ies in detail. We adopted the standard methods that are
recommended for systematic meta-analyses and used two
types of data analysis software programs to pool the
statistics.
As shown in Fig. 2, using the QUADAS-2 tool, the
quality of the 11 selected studies in this systematic
Fig. 9 A Deeks’ funnel plot asymmetry test for evaluation of potential publication bias for the QFT-IT assay. This plot indicated a low risk of
publication bias
Fig. 10 A Deeks’ funnel plot asymmetry test for evaluation of potential publication bias for the T-SPOT assay. This plot indicated a significant
potential risk of publication bias
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review was relatively polytropical, with 6 studies showing
a high risk of bias and 4 studies showing a high risk of
applicability concerns. Only 4 studies exhibited a prefer-
able quality and low risk of bias.
The pooled sensitivity and specificity of the QFT-IT
assay were 69 and 76 %, respectively, for diagnosing
ATB among HIV-seropositive patients after excluding
indeterminate results, which were similar to the re-
sults of previous studies in which the sensitivity and
specificity varied from 61–76.7 to 72–76.1 %, respect-
ively [14, 32]. These experiments suggested that the
QFT-IT assay was not sensitive and specific enough to
select real ATB patients or to rule out people who are
not suffering ATB among HIV-seropositive patients.
When adopting the QFT-IT, greater than 30 % of ATB
patients might be missed, and greater than 20 % of
non-ATB patients might be diagnosed as having TB.
The pooled sensitivity and specificity of the T-SPOT
assay were as high as 89 and 87 %, respectively, indi-
cating that the T-SPOT assay may have greater accur-
acy for distinguishing ATB cases among HIV-positive
patients than the QFT-IT assay. These results were
different from those of previous studies in which the
sensitivity and specificity varied from 65–77.4 to 63.1–70 %
[14, 32], respectively; this also showed that the T-SPOT
assay may be more effective in this review. The differences
in conclusions among this review and previous studies
might be attributed to more reasonable inclusion criteria
and latest references. Nevertheless, according to the small
number of studies included and the high heterogeneity, the
results calculated may not reflect the authentic accuracy of
the T-SPOT in the diagnosis of ATB among HIV-
seropositive patients. More experiments should be designed
in the future to confirm the effectiveness of the T-SPOT
assay.
The pooled ratios of the indeterminate QFT-IT and T-
SPOT results were 0.07 and 0.19 when using the fixed
effect model and 0.08 and 0.10 using the random effects
model, respectively. Overall, the QFT-IT assay appeared
to reduce the occurrence of indeterminate results among
HIV-seropositive individuals. This conclusion seems
more meaningful for diagnosis of LTBI, because an inde-
terminate result is the major limitation of the IGRA
inimmunosuppressed subjects. The reason for the
greater ratio of indeterminate results in the case of the
T-SPOT might be associated with technical error due to
the more sophisticated technical demand compared with
the QFT-IT assay [32].
The SROC curve for the T-SPOT assay was positioned
in the upper left corner, and the AUC was 0.93 (95 % CI,
0.90–0.95), which may suggest a more effective perform-
ance for distinguishing ATB cases among HIV-infected
individuals than the QFT-IT assay, which produced an
unsatisfactory AUC of 0.78 (95 % CI, 0.74–0.82).
However, as evidenced by the high heterogeneity among
the studies (I2 = 94.48 and 97.92 % for sensitivity and
specificity) and the small number of included studies,
the results may not accurately represent the perform-
ance of the T-SPOT assay. Furthermore, more additional
trials are required to determine the efficiency of the T-
SPOT assay.
The potential risk of publication bias was significant
(P = 0.04) for the T-SPOT assay in our meta-analysis, as
shown in Fig. 10. This indicated that preference may
have been given to claims supporting the hypotheses
in these publications when they were under review
[27–30]. No significant asymmetry was observed for
the QFT-IT assay (P = 0.47), which suggested a low
risk of publication bias.
Our systematic review also has some limitations. Due
to our strict selection and exclusion process, the num-
ber of included studies was only 11. Moreover, there
was heterogeneity among the studies included in our
analysis, and the difference between low/intermediate-
burden countries and high-burden countries may be
one of the reasons for the heterogeneity.
Conclusions
In summary, the latest evidence provided in this system-
atic review and meta-analysis shows the current limited
ability and accuracy of the IGRA for diagnosing ATB
and ruling out non-ATB cases; therefore, the T-SPOT
assay may be more accurate for distinguishing ATB
cases among HIV-infected individuals, while the QFT-IT
assay appears to reduce the occurrence of indeterminate
results. Thus, the IGRA does not appear to be optimal
for the clinical confirmation of ATB cases in HIV-
seropositive individuals until its efficiency is verified, al-
though modifications and additional trials may help to
improve its effectiveness.
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